Investor Presentaiton
Pfizer Offers Robust Differentiated Pipeline of Immuno-Inflammation
Potential Therapies
3C
D
Rheumatology
Rheumatoid Arthritis;
Lupus; Dermatomyositis; Psoriatic Arthritis
and Ankylosing Spondylitis
Gastroenterology
Currently Marketed Products
Inflectra™
infliximab
XELJANZ
[tofacitinib]
Enbrel
etanercept
Ixifi
infliximab
Investigational Assets
ADALIMUMAB-AFZB
Adalimumab biosimilar
a-IFNẞ
IRAK4/Ritlecitinib Combo
Covalent JAK3/TEC
Inflectra™
infliximab
TL1A
[tofacitinib)
RITLECITINIB
Ixifi
infliximab
Covalent JAK3/TEC
Inflammatory Bowel Disease (Crohn's Disease
& Ulcerative Colitis); Liver Fibrosis
XELJANZ
Medical Dermatology
Atopic Dermatitis; Acne;
Psoriasis; Alopecia Areata; Vitiligo;
Pfizer
Hidradenitis Suppurativa
•
•
eucrisa
crisaborole ointment 2%
Enbrel
etanercept
Not all products are approved in all jurisdictions.
Pfizer has rights to Enbrel outside the US and Canada
CIBINQO
(abrocitinib) tablets)
50ma
100ma
200m
Etrasimod*
S1P
RITLECITINIB
Covalent JAK3/TEC
Etrasimod*
S1P
PDE4+
* If acquired
12View entire presentation